Two trials in South Africa and Vietnam are informing imminent updates to the World Health Organisation’s guidance on tuberculosis preventive treatment (TPT) initiatives. These showed that giving the ...

Sydney researchers have found that Levofloxacin substantially reduces risk of drug-resistant tuberculosis. This discovery offers new hope against a disease that infects more than 400,000 people ...

There were an estimated 490,000 new cases of drug-resistant TB in 2016. Tuberculosis, a lung disease most often transmitted by breathing infected particles in the air, is the ninth leading cause of ...

The Clinical Practice Guidelines are the latest from the American Thoracic Society, the Centers for Disease Control and Prevention, European Respiratory Society and Infectious Diseases Society of ...

Tuberculosis remains one of the top infectious disease killers worldwide, a challenge amplified by drug-resistant forms of the disease. Now, in a major step forward, an international clinical trial ...

Children under 15 account for 4.3% of all new and relapsed tuberculosis (TB) cases in the WHO European Region, which includes Europe and Central Asia, compared with 3.9% in 2022, a 10% increase. The ...

Tuberculosis (TB), one of the leading infectious disease killers worldwide, has long posed a challenge, particularly with the rise of drug-resistant forms. However, new research offers fresh hope in ...

A new study uncovers vulnerabilities in drug-resistant TB, offering hope for improved treatments. Rutgers Health research has uncovered why a relatively new antibiotic for tuberculosis (TB) works ...

Shorter duration, fully oral treatment regimens for tuberculosis (TB) are now recommended for most adults and children. Updated joint guidelines from the American Thoracic Society, the CDC, European ...

An international research team headed by scientists at the University of British Columbia has demonstrated how a novel semi-synthetic compound derived from sanguinarine (SG), an alkaloid extracted ...

A clinical trial published in the New England Journal of Medicine showed that the oral antibiotic levofloxacin taken once-daily for six months substantially reduced the risk of developing ...